FDA Classifies Two Convenience Kit Recalls as Class I in October 2026: Contaminated Antiseptic Applicators Require Destruction of the Entire Kit

On 13 and 14 October 2026, the U.S. Food and Drug Administration (FDA) classified the convenience kit recalls by Medline and AVID Medical as Class I. Both recalls trace back to BD ChloraPrep antiseptic applicators contained in the kits, which may support fungal growth under certain environmental conditions. Both companies had previously instructed customers to apply a label and remove the affected component before use; the instruction has now changed to destruction of the entire kit, and inventory already distributed to hospitals must be re-screened.

The substantive change in these two recalls is not the product list. It is the corrective action.

On 13 October 2026 the FDA classified Medline's convenience kit recall as Class I. The following day, AVID Medical's recall of the same type was likewise classified as Class I. Both originate from BD ChloraPrep skin antiseptic applicators contained in the kits.

Before classification, the instruction to customers was to relabel: affix a notice to the outside of the kit and discard the affected applicator before use. After classification, the instruction became destruction of the entire kit.

Timeline: Early Alerts in August, Classification in October

The FDA proceeded in two steps. An early alert was issued for Medline on 24 August, and for AVID on 28 August. Both pages were marked as the FDA collecting information, with no classification assigned.

In October, both recalls were assigned to Class I. This is the most serious category in the FDA recall classification system. The meaning is specific: continued use may cause serious injury or death.

The Source: Two Lots of Antiseptic Applicators

On 6 June 2026, BD announced a voluntary recall of two lots of skin antiseptic products. One was ChloraPrep Clear 1 mL, REF 930480, lot 4032183, expiry 31 January 2027. The other was FREPP Clear 1.5 mL, REF 930299, lot 4073005, expiry 31 March 2027.

The FDA published the company announcement on 8 June. Both lots were shipped between March and June 2024 to distributors and hospitals.

The stated reason for the recall is measured: under certain environmental conditions, the product may support the growth of Aspergillus penicillioides. The risk description is not measured. If the fungus enters the bloodstream during catheter placement, the catheter will most likely have to be removed and the procedure repeated. A surgical site infection may require a second surgery plus long-term antifungal treatment.

Why the Instruction Changed from Relabeling to Whole-Kit Destruction

Medline's first notice, issued on 12 June, required relabeling. A customer letter dated 11 August changed the requirement to destruction of the entire kit. AVID followed the same path: relabeling was required on 22 July and changed to whole-kit destruction on 20 August.

Both companies stated that the change followed additional recall information subsequently provided by BD.

The relabeling approach pushes the judgment onto the individual in the operating room. If the label is not seen, the contaminated component reaches the sterile field. Whole-kit destruction moves that judgment back to the warehouse, at the cost of scrapping more material.

Specific Products Affected

Medline's public page identifies kits containing 930480/4032183 and 930299/4073005, with the complete list provided in a separate product table. AVID identifies the IV START KIT NON-STERILE, catalog number AVID KIT KRIV26-02, lot 1658437, UDI 10809160460481.

The requirements are consistent across both: check inventory, quarantine, complete and return the response form, then destroy the entire kit. Distributors that resold the product must also notify downstream customers.

As of 17 August and 20 August respectively, Medline and AVID both stated that they had received no reports of serious injury or death related to this matter. BD also stated in its June announcement that no adverse events had been reported. Class I classification is based on potential risk, not on the number of injuries that have already occurred.

An Easily Overlooked Detail

The same lots of antiseptic applicators are listed on the FDA page with a product type of Drugs. The convenience kits affected by them are handled as device recalls. The two tracks run in parallel, with different recall numbers, different responsible parties and different disposition requirements.

Companies that assemble convenience kits cannot rely on monitoring device recall databases alone. A recall of an upstream drug-classified component can invalidate an entire kit.

AIMEILI Regulatory Interpretation

These two Class I classifications illustrate how risk is allocated in a convenience kit: the kit assembler carries the recall obligation for the finished kit even though the root cause sits with an upstream component supplier. The FDA's determination rests on the hazard analysis rather than on the absence of reported adverse events, and the escalation from relabeling to whole-kit destruction reflects a judgment that a field-level instruction dependent on end-user compliance did not adequately control the risk. For regulatory affairs teams, the key point is that the corrective action itself is part of the recall record and will be assessed for adequacy; a change in corrective action after the initial notification should be documented with the supporting supplier information, communicated to consignees, and reflected in the recall status reporting.

Business Impact

• Inventory and distribution control: Class I status requires re-screening of all inventory at warehouses, distributors and hospitals, including stock that was previously handled under the relabeling instruction. Quarantine and destruction records should be retained.
• Downstream notification: Distributors that resold affected kits must notify their own customers and maintain records of the notification, since the change in corrective action supersedes any earlier relabeling instruction already passed down the chain.
• Component-level traceability: Kit assemblers need lot-level mapping between incoming components and finished kit lots, and a process to identify which finished kits contain a component lot named in an upstream recall.
• Supplier quality agreements: Contracts with component suppliers should require prompt notification of field actions, including those classified in a different product category such as drugs, and should define responsibility for downstream notification and destruction costs.
• Monitoring scope: Surveillance should cover drug as well as device recall databases where kits contain drug-classified components such as antiseptics, lubricants or saline.
• Commercial and contractual exposure: Whole-kit destruction affects larger volumes than component removal, and the cost allocation between assembler, distributor and component supplier should be reviewed against contractual terms.

Sources and Scope

Source: U.S. Food and Drug Administration (FDA), Convenience Kit Recall: Medline Removes Convenience Kits Affected by BD ChloraPrep Applicator Recall, 13 October 2026. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-removes-convenience-kits-affected-bd-chloraprep-applicator-recall

Source: U.S. Food and Drug Administration (FDA), Convenience Kit Recall: Avid Medical Removes Convenience Kits Affected by BD ChloraPrep Applicator Recall, 14 October 2026. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-avid-medical-removes-convenience-kits-affected-bd-chloraprep-applicator-0

Source: U.S. Food and Drug Administration (FDA), BD Issues Nationwide Recall for Specific Lots of ChloraPrep Clear Single Sterile 1 mL and FREPP Clear 1.5 mL Applicators Due to Microbial Contamination, published 8 June 2026. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bd-issues-nationwide-recall-specific-lots-chlorapreptm-clear-single-sterile-1-ml-and-frepptm-clear

Verification scope and access date: The three pages above were accessed on 19 October 2026, and the entries dated 13 October and 14 October in the FDA CDRH New: News and Updates list were checked.

Scope note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The official texts prevail, and the information may change with subsequent official updates.

Published: 19 October 2026, 09:33